Exact Sciences Corporation (EXAS)
| Market Cap | 17.58B |
| Revenue (ttm) | 1.71B |
| Net Income (ttm) | -864.77M |
| Shares Out | 171.49M |
| EPS (ttm) | -5.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,134,863 |
| Open | 103.00 |
| Previous Close | 102.25 |
| Day's Range | 97.79 - 103.27 |
| 52-Week Range | 71.86 - 159.54 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 148.88 (+51.6%) |
| Est. Earnings Date | Oct 26, 2021 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX ...
Financial Performance
In 2020, Exact Sciences's revenue was $1.49 billion, an increase of 70.19% compared to the previous year's $876.29 million. Losses were -$848.53 million, 910.2% more than in 2019.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for Exact Sciences stock is "Strong Buy." The 12-month stock price forecast is 148.88, which is an increase of 51.58% from the latest price.
News
3 Crash-Ready Stocks to Buy in September
History says this month can be scary. These stocks can get you through it.
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagn...
Exact Sciences to participate in September investor conferences
MADISON, Wis. , Sept. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to ...
Why Is Exact Sciences (EXAS) Down 9.4% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
3 Top Healthcare Stocks to Buy for August
With excellent prospects, these three companies are built to last and today's prices are attractive.
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence ...
Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test D...
MADISON, Wis., Aug. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-revie...
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of -43.06% and 3.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences: Q2 Earnings Insights
Shares of Exact Sciences (NASDAQ:EXAS) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.59% over the past year to ($1.03), whi...
Exact Sciences Announces Second Quarter 2021 Results
MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared...
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Exact Sciences (EXAS)
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Exact Sciences schedules second quarter 2021 earnings call
MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. fi...
Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160
Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular diagnostics company, has se...
Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Exact Sciences (EXAS) Reveals Promising Data on Cologuard
Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.
4 Unstoppable Healthcare Stocks to Buy on the Dip
They're well below peak levels set earlier this year. But they could be huge winners over the long run.
Exact Sciences to participate in June investor conferences
MADISON, Wis., May 24, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to par...